These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 7380176)

  • 1. Complement metabolism in chronic liver disease: catabolism of C1q in chronic active liver disease and primary biliary cirrhosis.
    Potter BJ; Elias E; Thomas HC; Sherlock S
    Gastroenterology; 1980 May; 78(5 Pt 1):1034-40. PubMed ID: 7380176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complement activation in chronic liver disease.
    Munoz LE; De Villiers D; Markham D; Whaley K; Thomas HC
    Clin Exp Immunol; 1982 Mar; 47(3):548-54. PubMed ID: 7083631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impaired opsonization by serum from patients with chronic liver disease.
    Wyke RJ; Rajkovic IA; Williams R
    Clin Exp Immunol; 1983 Jan; 51(1):91-8. PubMed ID: 6339126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fast liver catabolism of C1q in patients with paraproteinaemia and depletion of the classical pathway of complement.
    Schifferli JA; Pascual M; Steiger G; Schapira M; Ryser JE; Estreicher J; Dash A
    Clin Exp Immunol; 1987 Jul; 69(1):188-97. PubMed ID: 3498586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Hepatitis B surface antigen in chronic active hepatitis and primary biliary cirrhosis].
    Burlev VA; Nasonov EL; Golosova TV; Podymova SD; Somova AV
    Sov Med; 1978 May; (5):39-45. PubMed ID: 675321
    [No Abstract]   [Full Text] [Related]  

  • 6. Neutrophil phagocytic and bactericidal function in primary biliary cirrhosis and other chronic liver diseases.
    De Fernandez MA; Clark A; Triger DR
    Clin Exp Immunol; 1987 Mar; 67(3):655-61. PubMed ID: 3608234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Receptor specific clearance by the reticuloendothelial system in chronic liver diseases. Demonstration of defective C3b-specific clearance in primary biliary cirrhosis.
    Jaffe CJ; Vierling JM; Jones EA; Lawley TJ; Frank MM
    J Clin Invest; 1978 Nov; 62(5):1069-77. PubMed ID: 711852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatic copper content, urinary copper excretion, and serum ceruloplasmin in liver disease.
    Ritland S; Steinnes E; Skrede S
    Scand J Gastroenterol; 1977; 12(1):81-8. PubMed ID: 834974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significance of serum complement levels in chronic liver disease.
    Finlayson ND; Krohn K; Fauconnet MH; Anderson KE
    Gastroenterology; 1972 Oct; 63(4):653-9. PubMed ID: 4116547
    [No Abstract]   [Full Text] [Related]  

  • 10. Hypercatabolism of the third component of complement in patients with primary biliary cirrhosis.
    Potter BJ; Elias E; Jones EA
    J Lab Clin Med; 1976 Sep; 88(3):427-39. PubMed ID: 956695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proceedings: C3 metabolism in HBsAg positive and negative chronic active liver disease (CALD).
    Elias E; Potter BJ; Thomas HC; Sherlock S
    Gut; 1976 May; 17(5):389. PubMed ID: 1278736
    [No Abstract]   [Full Text] [Related]  

  • 12. Expression of ras and c-myc oncoproteins and hepatitis B surface antigen in human liver disease.
    Tiniakos D; Spandidos DA; Yiagnisis M; Tiniakos G
    Hepatogastroenterology; 1993 Feb; 40(1):37-40. PubMed ID: 8462926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential findings for CD14-positive hepatic monocytes/macrophages in primary biliary cirrhosis, chronic hepatitis C and nonalcoholic steatohepatitis.
    Leicester KL; Olynyk JK; Brunt EM; Britton RS; Bacon BR
    Liver Int; 2006 Jun; 26(5):559-65. PubMed ID: 16762000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Liver-specific lipoprotein component level in circulating immune complexes in liver diseases].
    Uĭbo RM; Nutt KhR; Priukk TIa
    Sov Med; 1989; (11):14-6. PubMed ID: 2533998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Protein-copper complex in primary biliary cirrhosis and other chronic diffuse diseases of the liver].
    Loginov AS; Aruin LI; Shepeleva SD
    Arkh Patol; 1980; 42(4):50-5. PubMed ID: 7396755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of medroxyprogesterone on the liver function and drug metabolism of patients with primary biliary cirrhosis and chronic active hepatitis.
    Sotaniemi EA; Hynnynen T; Ahlqvist J; Ahokas JT; Puoskari U; Pelkonen I
    J Med; 1978; 9(2):117-28. PubMed ID: 276564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HBsAg-associated albumin receptors and antialbumin antibodies in sera of patients with liver disease.
    Thung SN; Gerber MA
    Gastroenterology; 1981 Feb; 80(2):260-4. PubMed ID: 6161062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cryoglobulinemia in chronic liver diseases.
    Shoenfeld Y; Berliner S; Neeman A; Kadish U; Pinkhas J
    Am J Gastroenterol; 1980 Nov; 74(5):439-40. PubMed ID: 7234822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolism of the third component of complement in acute type B hepatitis, HBs antigen positive glomerulonephritis, polyarteritis nodosum, and HBs antigen positive and negative chronic active liver disease.
    Thomas HC; Potter BJ; Elias E; Sherlock S
    Gastroenterology; 1979 Apr; 76(4):673-9. PubMed ID: 33867
    [No Abstract]   [Full Text] [Related]  

  • 20. Transfer factor in the attempted treatment of patients with HBsAg-positive chronic liver disease.
    Jain S; Thomas HC; Sherlock S
    Clin Exp Immunol; 1977 Oct; 30(1):10-5. PubMed ID: 606432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.